Texas medical-cannabis expansion now has named operators, not just a promise

Texas has finished the selection process and named the new entrants

Texas has now identified all 12 companies chosen for the expansion of its low-THC medical-cannabis program. With the Department of Public Safety completing the second and final selection round on April 1, the state has moved from a small, tightly limited system with three active operators to a named field that could eventually reach 15 license holders.

That is the news. Not that Texas suddenly has 15 functioning medical-cannabis businesses. It does not. The state still has three active licensed dispensaries, listed by DPS as Fluent, Texas Original, and Goodblend. What changed is that the expansion required by HB 46 is no longer an abstract instruction from the legislature. It now has companies attached to it, deadlines behind it, and a replacement mechanism if some winners do not make it to launch.

The April 1 announcement added the final three conditional selections to the nine companies announced in December. DPS said those Phase II selections were GTI Texas, which operates under the RISE brand, Texas Medica Collective, and Cresco Labs Texas. The earlier Phase I group included, among others, Verano Texas, Trulieve TX, and PC TX OPCO, doing business as PharmaCann. Together, the two rounds complete the 12 additional selections required on top of the program's three current operators.

This matters now because the expansion finally has a practical shape. A medical-cannabis market with 145,997 registered patients in March 2026 and 944 approved physicians is no longer waiting on a basic question of how many companies the state intends to allow. The state has answered that question. The market is still incomplete, but it is no longer undefined.

For businesses around the sector, that is a meaningful shift. Founders, multistate operators, landlords, equipment vendors, packaging suppliers, and service firms can now see who is in the queue. Existing operators can now see who may be joining them. Patients and doctors can at least see that the expansion has moved past bill text and into administrative selection.

Just as important, DPS has been explicit about the limit of this moment. Conditional status does not authorize operations. These companies are selected, not yet selling. That distinction will shape every serious read of Texas from here.

HB 46 did more than raise the license count, and the timing now matters

The structure behind this change is straightforward once the state language is translated into normal terms. HB 46 required Texas to expand its Compassionate Use Program to a total of 15 licenses. Texas uses the term "dispensing organization" for those licensed businesses. In practice, these are the companies allowed to serve registered patients under the program.

The law did not leave the rollout open-ended. It required the state to identify at least nine new licenses by Dec. 1, 2025 and at least three more by Apr. 1, 2026. DPS has now met both deadlines. That is why the April 1 update matters more than a routine agency posting. It marks the point at which the legislature's expansion timetable was fully carried through into named selections.

The law also changed more than the number of operators. According to DPS's own summary of the legislation, HB 46 expanded qualifying conditions, allowed satellite locations, and was intended to improve statewide patient access and the availability of different dosage forms, meaning the kinds of products patients can receive within the program's rules. More licenses alone would not necessarily solve access in a state as large as Texas. The satellite-location provision matters because it opens the door to more points of service beyond a single central site.

That is the operational logic of the bill. Texas had a program with a growing patient registry, a growing physician base, and only three active operators. The state response was not simply to let those three get larger. It was to create a much bigger licensed field and give that field a legal framework for wider physical reach.

Still, the state has not handed the market a finished system. The selected companies are conditional licensees. DPS said clearly that conditional status does not yet permit operations. Before any of these businesses become working participants in the market, they still need to clear the state's licensing and buildout process.

That is where the 24-month rule becomes important. Under the statute, issued licensees must begin dispensing within 24 months or risk replacement. In plain terms, a company cannot sit on a Texas medical-cannabis license indefinitely. If it wins a license, gets it issued, and then fails to get into operation within the required period, the state can move on to another applicant from an eligibility list.

That replacement mechanism is one of the most consequential parts of the expansion even though it received less attention than the license count. It tells the market that Texas is not only selecting companies. It is also reserving the power to remove nonperformers from the line if they cannot execute. For a program moving from scarcity to controlled expansion, that is a serious discipline.

The other important boundary is what HB 46 did not do. Texas remains a medical-only, low-THC market. This is not adult-use legalization by another route. The commercial opportunity is expanding, but it is still defined by patient registration, physician participation, product limits, and state oversight.

The commercial field is now visible, but the hard work starts after selection

For operators, the shift is immediate. Texas is no longer just a future headline about eventual scale. It is now a defined contest with incumbents and conditionally selected challengers. The incumbents are known: Fluent, Texas Original, and Goodblend. The new field now has named entrants that include some of the most recognizable multistate cannabis companies in the US, such as Verano, Trulieve, PharmaCann, GTI, and Cresco, alongside other selected applicants such as Texas Medica Collective.

That changes the quality of every conversation around the state. A business looking at cultivation equipment, extraction hardware, security systems, compliance software, lab services, transport, packaging, or real estate is no longer looking at Texas as a vague medium-term possibility. There is now a shortlist of companies that may need facilities, staff, supply contracts, and distribution plans. The opportunity has become more concrete, even if the revenue timeline has not.

It also changes the risk picture. In many cannabis markets, license counts attract attention before the operating conditions do. Texas now has both. The patient side of the program is not trivial. DPS shows 145,997 registered patients in March 2026. That means people already approved to receive product under the program. The physician side is also substantial, with 944 approved doctors in February and March 2026. Those are real demand and prescribing numbers, not a speculative future base.

But those numbers do not automatically translate into an easy launch. A larger patient registry makes the state more attractive. It does not remove the cost, time, and regulatory burden of building a compliant operation in a tightly supervised medical program. More physicians helps. It does not guarantee that prescribing will broaden at the same pace as licensing. Product range may improve under the new law, but product development, production, and distribution still have to be built and approved.

This is where Texas becomes more interesting than a simple license-expansion story. The state is trying to solve several problems at once: access, capacity, competition, geography, and product availability. The extra licenses address competition and capacity on paper. Satellite locations could address geography. Expanded qualifying conditions could widen the patient base further. Broader dosage-form availability could make the program more usable for patients already inside it. But these are connected pieces. If one part lags, the practical benefit of the others is reduced.

For existing operators, the message is clear enough. A market that had only three active licensees for years is preparing for a very different competitive environment. That does not mean the incumbents are suddenly weak. They have operating history, existing patient relationships, infrastructure, and practical experience inside Texas rules. But their protected position is being diluted by policy design.

For the conditional winners, the message is equally clear. Selection is not the finish line. Texas has given them access to a lane, not the market itself. They still need final licensing, buildout, staffing, supply chains, physician outreach, and an operating footprint that can stand up in a state where distance and logistics matter. If they fail to execute, the statute gives DPS a route to replace them.

For investors and lenders, the main change is not certainty. It is visibility. Texas now has identified counterparties and a statutory clock. That makes due diligence possible in a way that a legislative promise alone never did. It also makes underperformance easier to detect, because the state has tied the expansion to deadlines and operational requirements.

Texas now has a roster and a clock, but not yet a finished market

The easiest way to misread this moment is to count to 15 and assume the market has already arrived. The evidence says otherwise. Texas has three active operators today and 12 additional companies with conditional selections. That is a real expansion. It is not the same as 12 new functioning businesses serving patients across the state.

Still, this is the point at which Texas becomes legible. For years, the state's medical-cannabis program could be described as politically alive but commercially narrow. The law changed that in 2025 by ordering a much larger field. The agency has now carried out that instruction on schedule. As of April 1, the expansion is no longer waiting for names.

What happens next will matter more than the selection headlines. The state will need to turn conditional winners into issued licensees. Those licensees will need to build, open, and begin dispensing inside the 24-month window set by law. Patients will need actual access points, not just promised coverage. Doctors will need to keep participating. Product availability will need to improve in ways that patients can feel. And the state will need to use its replacement authority if selected companies cannot convert a paper win into an operating business.

That is the real significance of this phase. Texas has moved past legislative optionality. It has entered the narrower and more demanding stage where names, capital, compliance, logistics, and execution decide the outcome. In a market this large, that is a more consequential test than the bill itself.

The expansion should therefore be read as an operator map with conditions attached. It is concrete enough to reset business planning and competitive expectations. It is not mature enough to be treated as settled market capacity. Texas has finally drawn the field. The next two years will show whether that field can actually serve the state it was designed for.